New Delhi, February 25 The Science Department's Technology Development Board on Wednesday approved financial assistance to Karnataka-based Biovet Pvt Ltd to develop and commercialize veterinary reproductive hormones at a dedicated manufacturing facility.
These hormones include gonadotropin-releasing hormone (GnRH) analogues – Gonadorelin and Buserelin acetate – and the prostaglandin analogue Cloprostenol, which play a significant role in livestock reproduction management and therapeutic interventions for reproductive disorders.
"Currently, there is no commercial-scale production of these hormones, which are developed in India, leading to dependence on imports and higher costs for farmers. The proposed facility will enable domestic manufacturing of hormone agonists, reducing import reliance, lowering costs, and ensuring wider accessibility for livestock farmers," an official said.
The project, "Development and Commercialization of Veterinary Hormones," aims to strengthen India's capabilities in high-value veterinary pharmaceuticals by integrating indigenous process development with commercial-scale production.
It will leverage Biovet's expertise in biotechnology-based veterinary products, including biologicals and vaccines, to expand into a specialized area of hormone and therapeutic product manufacturing.
In a statement, Rajesh Kumar Pathak, secretary of the Technology Development Board, said, "Developing indigenous veterinary hormone manufacturing capacity is strategically important for strengthening animal husbandry and supporting farmers' livelihoods.
"Through this project, the TDB is facilitating import substitution, promoting domestic biotechnology capabilities, and enabling affordable access to critical reproductive therapeutics."